NeuroPace Debt to Equity Ratio 2020-2024 | NPCE
Current and historical debt to equity ratio values for NeuroPace (NPCE) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. NeuroPace debt/equity for the three months ending December 31, 2024 was 7.43.
| NeuroPace Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2024-12-31 | $0.09B | $0.01B | 10.81 |
| 2024-09-30 | $0.09B | $0.01B | 8.80 |
| 2024-06-30 | $0.09B | $0.01B | 8.55 |
| 2024-03-31 | $0.09B | $0.01B | 5.89 |
| 2023-12-31 | $0.09B | $0.02B | 4.21 |
| 2023-09-30 | $0.08B | $0.02B | 5.07 |
| 2023-06-30 | $0.08B | $0.02B | 3.82 |
| 2023-03-31 | $0.08B | $0.03B | 2.87 |
| 2022-12-31 | $0.08B | $0.04B | 2.28 |
| 2022-09-30 | $0.08B | $0.04B | 1.78 |
| 2022-06-30 | $0.07B | $0.05B | 1.24 |
| 2022-03-31 | $0.07B | $0.06B | 1.05 |
| 2021-12-31 | $0.06B | $0.07B | 0.82 |
| 2021-09-30 | $0.06B | $0.08B | 0.73 |
| 2021-06-30 | $0.06B | $0.09B | 0.66 |
| 2021-03-31 | $0.21B | $-0.16B | -1.32 |
| 2020-12-31 | $0.20B | $-0.15B | -1.38 |
| 2020-09-30 | $0.00B | $0.00B | 0.00 |
| 2020-06-30 | $0.00B | $0.00B | 0.00 |
| 2020-03-31 | $0.00B | $0.00B | 0.00 |
| 2019-12-31 | $0.15B | $-0.13B | -1.16 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED INSTRUMENTS | $0.392B | $0.080B |
| NeuroPace Inc. is a commercial-stage medical device company. It is focused on developing products to treat and transform the lives of patients suffering from epilepsy. NeuroPace Inc. is based in MOUNTAIN VIEW, Calif. | |||